Focus: Reliance Life Sciences is a biosimilar and generic oncology/hematology focused biotech company headquartered in Navi Mumbai, India. The company specializes in bringing post-LOE chemotherapy and targeted cancer drugs to market.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
No open roles listed right now. Follow Reliance Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Proteasome inhibitor for multiple myeloma; established market with sustained demand but mature competitive landscape.
Help build intelligence for Reliance Life Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Reliance Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Antifolate drug for NSCLC; core oncology asset with proven clinical utility in combination regimens.
DNA methyltransferase inhibitor for MDS; niche hematology indication with limited patient population.
Hypomethylating agent for MDS; established therapy with ongoing standard-of-care status in hematologic malignancies.
Oral fluoropyrimidine for solid tumors; widely used in combination chemotherapy with durable market presence.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub